• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Dr Brandon Shank: Reimbursement Challenges With Biosimilars

Video

Brandon Shank, PharmD, MPH, BCOP, Clinical Pharmacy Specialist, discusses the potential for reimbursement challenges with biosimilars.

Transcript:

Will there be reimbursement challenges with biosimilar products?

I think it’s too soon right now to say, exactly. It is a very complicated payer system, and there are a lot of incentives—for the hospitals, the patients, and the insurance companies. I hope that patients will see some of the cost savings, as well as insurances, and hospitals will be incentivized, hopefully, to add these agents on to their formulary and pass on the cost savings to the entire health care system both at a payer base and a patient-care level.

Recent Videos
Ivo Abraham, PhD, RN.
Ivo Abraham, PhD, RN.
Ivo Abraham, PhD, RN.
Ivo Abraham, PhD, RN.
Ivo Abraham, PhD, RN
Ivo Abraham, PhD, RN.
Jeffrey Casberg, MS, RPh
Jeffrey Casberg, RPh, MS.
Jeffrey Casbery, IPD Analytics
Lakesha Farmer, PharmD
Related Content
© 2024 MJH Life Sciences

All rights reserved.